Intelligence Profile
Research Papers
Key Research Papers and Clinical Trials
Recent research on kisspeptin-10 has explored several therapeutic applications, though the evidence base remains relatively limited with small-scale studies.
Clinical Applications and Diagnostic Use
Several studies have investigated kisspeptin-10's role in reproductive health. One 2026 study examined the kisspeptin-10/basal LH ratio as a diagnostic tool for differentiating central precocious puberty from premature thelarche, suggesting potential clinical utility in pediatric endocrinology. Another study tracked dynamic changes of kisspeptin during controlled ovarian hyperstimulation in women with polycystic ovary syndrome, correlating these changes with treatment outcomes.
Metabolic and Cardiovascular Effects
Research has expanded beyond reproductive applications to explore metabolic functions. A 2026 study investigated the role of Kiss1 neurons in regulating metabolism and energy balance. Additionally, researchers examined kisspeptin-10's effects on human cardiac fibroblast cultures, specifically its regulation of glycosaminoglycan and decorin content, suggesting potential cardiovascular applications.
Cancer Research
Laboratory studies have explored kisspeptin-10's anti-cancer properties. One 2026 study found that exogenous kisspeptin-10 inhibited ovarian cancer progression by targeting the SP1-hTERT-ZEB1 regulatory axis, though this research appears limited to cell culture models.
Clinical Trials
Several Phase 3 clinical trials have been completed examining kisspeptin's effects on hormonal regulation:
- Studies investigating the link between kisspeptin signaling sensitivity and pubertal onset in boys
- Research on kisspeptin-10 and insulin secretion in men
- Age-dependent changes in hypothalamic-pituitary-gonadal axis responsiveness
However, some Phase 1 trials evaluating kisspeptin's effects on glucose-stimulated insulin secretion were withdrawn, indicating potential challenges in this research area.
Comparative Studies
Research has also compared different kisspeptin analogs, with one 2026 study finding that the kisspeptin analog C6 produced greater tachyphylaxis and transcriptional activation compared to both kisspeptin-10 and kisspeptin-54.
The research landscape for kisspeptin-10 shows promise across multiple therapeutic areas, though many studies appear to be in early phases or limited to laboratory models. More robust clinical evidence may be needed to establish definitive therapeutic applications.